News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|December 23, 2024

Overview of PPD and Current Management Practices

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss how postpartum depression (PPD) is recognized and managed, highlighting current diagnostic practices, treatment options, and the role of emerging therapies in improving outcomes for affected individuals.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

A New Option: Getting TDM Data Faster

ByJonathan M. Meyer, MD, DLFAPA

December 1st 2025

Using TDMs to Improve Care and Communication

ByJonathan M. Meyer, MD, DLFAPA

November 20th 2025

Why Therapeutic Drug Monitoring Is Important for Antipsychotics

ByJonathan M. Meyer, MD, DLFAPA

November 13th 2025

1 KOL is featured in this series

Future Directions For Prescription Digital Therapeutics

ByGustavo Alva, MD, DFAPA,Erin Crown, MHS, PA-C, Psych-CAQ,Linda Trinh, DNP, MPH, FNP-C, PMHNP-BC

September 30th 2025

1 KOL is featured in this series

Talking to Patients about Prescription Digital Therapeutics

ByGustavo Alva, MD, DFAPA,Erin Crown, MHS, PA-C, Psych-CAQ,Linda Trinh, DNP, MPH, FNP-C, PMHNP-BC

September 30th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

© 2025 MJH Life Sciences^®

All rights reserved.